Сигурна ли е Eisai Co дивидентата?
Eisai Co увеличава дивидентата си от 1 години.
През последните 10 години Eisai Co ги е увеличил със средно 0,647 % годишно увеличен.
На 5-годишна база нарасна разпределението с 0 %.
Анализаторите очакват за текущата финансова година ръст от 0,300%.
Eisai Co Aktienanalyse
Какво прави Eisai Co?
Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company.
Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries.
Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world.
The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases.
Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA.
Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery.
Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields.
Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable.
Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co е една от най-популярните компании на Eulerpool.com.Акционерните спестовни планове предлагат привлекателен начин за инвеститорите да изградят дългосрочно богатство. Едно от основните предимства е така нареченият ефект на средната цена при покупка: като редовно се инвестира фиксирана сума в акции или акционерни фондове, автоматично се купуват повече дялове, когато цените са ниски, и по-малко, когато са високи. Това може да доведе до по-изгодна средна цена на дял във времето. Освен това акционерните спестовни планове позволяват дори на малките инвеститори да получат достъп до скъпи акции, тъй като могат да участват с малки суми. Редовната инвестиция също насърчава дисциплиниран подход към инвестирането и помага да се избегнат емоционални решения, като импулсивно купуване или продаване. Допълнително инвеститорите се възползват от потенциалното увеличение на стойността на акциите, както и от дивидентните изплащания, които могат да бъдат реинвестирани, усилвайки компаундиращия ефект и така растежа на инвестирания капитал.